Neurologische Klinik und Poliklinik
Refine
Has Fulltext
- yes (75)
Is part of the Bibliography
- yes (75)
Year of publication
Document Type
- Journal article (75)
Language
- English (75)
Keywords
- Fabry disease (11)
- neuropathic pain (8)
- cytokines (5)
- fibromyalgia syndrome (5)
- pain (5)
- Parkinson's disease (4)
- skin punch biopsy (4)
- Fabry-associated pain (3)
- Medizin (3)
- autoantibodies (3)
- depression (3)
- enzyme replacement therapy (3)
- gene expression (3)
- mouse model (3)
- small fiber neuropathy (3)
- B7-H1 (2)
- Fibromyalgia syndrome (2)
- Langerhans cells (2)
- Neuropathy (2)
- antibodies (2)
- anxiety (2)
- autoantibody (2)
- biomarker (2)
- chronic pain (2)
- diagnosis (2)
- expression (2)
- glycine receptor (2)
- inflammation (2)
- inflammatory neuropathy (2)
- microRNA (2)
- mouse models (2)
- nerve fibers (2)
- neurofascin (2)
- neurology (2)
- neuropathy (2)
- opioids (2)
- passive transfer (2)
- polyneuropathy (2)
- renal system (2)
- skin biopsy (2)
- 65-kda isoform (1)
- A-delta fibers (1)
- Agalsidase beta therapy (1)
- Alpha galactosidase (1)
- Anderson-Fabry Disease (1)
- Antiparanodal Autoantibodies (1)
- Anxiety (1)
- Arterial Diameters (1)
- Axonal degeneration (1)
- Aδ- and C-fibers (1)
- Beta-glucocerebrosidase (1)
- CCI (1)
- CIDP (1)
- CLN3 (1)
- CNS imaging (1)
- CRPS (1)
- Charcot–Marie–Tooth disease type 1A (1)
- CholinomiRs (1)
- Clinical manifestations (1)
- Cognitive behavior (1)
- Corneal confocal microscopy (1)
- Cytokines (1)
- D313Y genotype (1)
- Delphi procedure (1)
- Demyelinating peripheral neuropathy (1)
- Diabetes mellitus (1)
- Diabetic polyneuropathy (1)
- Diagnosis (1)
- Disease (1)
- English version (1)
- Enzyme replacement therapy (1)
- Epilepsy (1)
- FOSMN (1)
- Fabry (1)
- Fabry cardiomyopathy (1)
- Fabry genotype (1)
- Fabry nephropathy (1)
- Fabry phenotype (1)
- Factor messenger-RNA (1)
- Fibromyalgie (1)
- Gene-expression (1)
- Gland (1)
- Glutamic-acid decarboxylase anxiety (1)
- Guillain-Barre-Syndrome (1)
- Guillain-Barré syndrome (1)
- Heat Hyperalgesia (1)
- IENFD (1)
- IL-15 (1)
- IL-4 (1)
- IVIg (1)
- Identification (1)
- IgG4 (1)
- Immune system (1)
- Innervation (1)
- Interleukin-6 (1)
- Interleukin-6-Deficient mice (1)
- LIMP-2 (1)
- Leukemia Inhibitory Factor (1)
- MDL-28170 (1)
- MIBG scintigraphy (1)
- MIC ligands (1)
- MMP9 (1)
- Mechanisms (1)
- Mediated Inflammatory Hyperalgesia (1)
- Merkel cell density (1)
- Mice (1)
- Migräne (1)
- Monopolar depression (1)
- Motor nerve biopsy (1)
- NF-κB (1)
- NKG2D (1)
- NKG2D ligands (1)
- NMOSD (1)
- NPSI (1)
- Necrosis-factor-Alpha (1)
- Nerve growth-factorcopy (1)
- Neuralgie (1)
- Neurotrophic factors (1)
- Nodo-parandopathy (1)
- Oncostatin-M-Receptor (1)
- Opioid receptor (1)
- Outcome survey (1)
- PD-L1 (1)
- PET (1)
- Pain (1)
- Pain questionnaire (1)
- Pain-related evoked potentials (1)
- Peripheral Inflammation (1)
- Pharmacological management (1)
- Quality of life (1)
- RECK (1)
- RNA extraction (1)
- Randomized controlled trial (1)
- Rat Sensory Neurons (1)
- Receptors (1)
- Rheumatoid-Arthritis (1)
- Rochester diabetic neuropathy (1)
- SNI (1)
- Schwann cell (1)
- Schwann-cells (1)
- Serotonin (1)
- Sjorgens-syndrome (1)
- Skin biopsy (1)
- Small fiber neuropathy (1)
- Small-fiber neuropathy (1)
- T cell activation (1)
- TNFα (1)
- Thermal Hyperalgesia (1)
- Treatment (1)
- Tryptophan hydroxylase-2 (Tph2) (1)
- X-chromosomal inactivation (1)
- adsorption (1)
- afferents (1)
- aggression (1)
- algorithm (1)
- allodynia (1)
- alpha-galactosidase A (1)
- alpha-synuclein (1)
- amygdala (1)
- amyotrophic-lateral-sclerosis (1)
- analgesia (1)
- animal behavior (1)
- antagomir (1)
- anti-contactin-1 (1)
- aquaporin 4 (1)
- atrophy Kennedys-disease (1)
- autoantibody (aAb) (1)
- autoimmune nodopathy (1)
- back pain (1)
- behavioral disorders (1)
- binding (1)
- binding analysis (1)
- biopsies (1)
- biopsy (1)
- blood CSF barrier (1)
- blood flow (1)
- blood nerve barrier (1)
- brain (1)
- burning pain (1)
- calpain (1)
- capsaicin (1)
- care (1)
- celiac disease (1)
- cell binding assay (1)
- central nervous system (1)
- cerebral arteries (1)
- cerebrospinal fluid (1)
- cholinergic system (1)
- chronic constriction nerve injury (1)
- chronic constriction nerve injury (CCI) (1)
- chronic stress (1)
- classification (1)
- claudin-1 (1)
- clinical neurology (1)
- cognitive impairment (1)
- complement deposition (1)
- complex regional pain syndrome (1)
- contactin (1)
- coping (1)
- corneal confocal microscopy (1)
- cortical activation (1)
- criteria (1)
- crossover trial (1)
- cue (1)
- cutaneous innervation (1)
- cutaneous patch (1)
- cutting edge (1)
- dermal B cells (1)
- diagnosis in Fabry disease (1)
- diagnostic markers (1)
- disability (1)
- disorder (1)
- enzyme assays (1)
- enzyme-linked immunoassays (1)
- epidermis (1)
- extracellular domain (1)
- facial pain (1)
- fear (1)
- fear memory (1)
- female Fabry patients (1)
- females (1)
- fibers (1)
- fibromyalgia (1)
- flotillin-1 lipid rafts (1)
- gene variant (1)
- gene-by-environment interaction (1)
- genetics (1)
- genotype/phenotype correlation (1)
- gephyrin (1)
- globotriaosylceramide (1)
- glucocerebrosidase mutation (1)
- glycine receptor (GlyR) (1)
- glycine receptor autoantibodies (1)
- glycosylation (1)
- guidelines (1)
- hernia repair (1)
- hippocampus (1)
- human muscle-cells (1)
- humans (1)
- hyperalgesia (1)
- hyperekplexia (1)
- idiopathic inflammatory myopathies (1)
- immune system (1)
- immunofluorescence (1)
- immunomodulation (1)
- inflammatory demyelinating polyradiculoneuropathy (1)
- inherited metabolic disorders (1)
- innervation (1)
- interference (1)
- intraepidermal nerve fiber density (1)
- intraepidermal nerve fibre density (1)
- intrathecal application (1)
- intravenous immunoglobulin (1)
- ion channels (1)
- ischemic stroke (1)
- learning (1)
- lesions (1)
- long-term pain (1)
- lymphokine-activated killer (1)
- lyso-Gb3 (1)
- lysosomal storage disease (1)
- macrophages (1)
- magnetic resonance imaging (1)
- management (1)
- mast cells (1)
- metaanalysis (1)
- miR-182-5p (1)
- miR-21 (1)
- miRNA (1)
- miRNA expression patterns (1)
- miRNA polymorphisms (1)
- miRNA-based analgesic (1)
- miRNA-based diagnostics (1)
- mice (1)
- migraineur (1)
- mixed fiber neuropathy (1)
- motor proteins (1)
- movement disorders (1)
- multiple sclerosis (1)
- multiple system atrophy (1)
- musk myasthenia gravis (1)
- mutation (1)
- near-infrared spectroscopy (1)
- nerve biopsy (1)
- nerve fibres (1)
- nerve tumor (1)
- nerve-fibers (1)
- neuralgia (1)
- neurofilament light chain (1)
- neuroleukemiosis (1)
- neurological examination (1)
- neuronopathy (1)
- neurons (1)
- nociceptive Schwann cells (1)
- nociceptor sensitization (1)
- node of ranvier (1)
- ontactin 1 (1)
- opioid (1)
- pain questionnaire (1)
- pain sensation (1)
- pain-associated behavior (1)
- pain-related evoked potentials (1)
- paranodopathy (1)
- pathology section (1)
- pathways (1)
- periperal nerve (1)
- peripheral nerve involvement (1)
- peripheral nervous system (1)
- polymorphism (1)
- polymyositis (1)
- postherpetic neuralgia (1)
- presynaptic inhibition (1)
- progressive encephalitis with rigidity and myoclonus (PERM) (1)
- proinflammatory cytokine (1)
- quantitative sensory testing (1)
- qutenza (1)
- receptor (1)
- recommendations (1)
- reflex (1)
- reinnervation (1)
- religiosity (1)
- reproducible outcome measure (1)
- risk factors (1)
- scale (1)
- sciatic nerves (1)
- shingles (1)
- skin diseases (1)
- skin tumors (1)
- small-fiber neuropathy (1)
- spinal cord (1)
- spinal-cord-injury (1)
- startle disease (1)
- stiff-person syndrome (SPS) (1)
- stroke (1)
- substance-P (1)
- swimming (1)
- switch (1)
- synaptic transmission (1)
- systematic review (1)
- tissue resident T cells (1)
- transient receptor potential vanilloid 1 (TRPV1) (1)
- trigeminal nerve (1)
- trigeminal neuropathy (1)
- tumor immunity (1)
- validation (1)
- white blood cells (1)
Institute
- Neurologische Klinik und Poliklinik (75)
- Institut für Klinische Neurobiologie (7)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (7)
- Medizinische Klinik und Poliklinik I (5)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (4)
- Institut für Klinische Epidemiologie und Biometrie (2)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Rudolf-Virchow-Zentrum (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
Sonstige beteiligte Institutionen
Rationale
While brain serotonin (5-HT) function is implicated in gene-by-environment interaction (GxE) impacting the vulnerability-resilience continuum in neuropsychiatric disorders, it remains elusive how the interplay of altered 5-HT synthesis and environmental stressors is linked to failure in emotion regulation.
Objective
Here, we investigated the effect of constitutively impaired 5-HT synthesis on behavioral and neuroendocrine responses to unpredictable chronic mild stress (CMS) using a mouse model of brain 5-HT deficiency resulting from targeted inactivation of the tryptophan hydroxylase-2 (Tph2) gene.
Results
Locomotor activity and anxiety- and depression-like behavior as well as conditioned fear responses were differentially affected by Tph2 genotype, sex, and CMS. Tph2 null mutants (Tph2\(^{−/−}\)) displayed increased general metabolism, marginally reduced anxiety- and depression-like behavior but strikingly increased conditioned fear responses. Behavioral modifications were associated with sex-specific hypothalamic-pituitary-adrenocortical (HPA) system alterations as indicated by plasma corticosterone and fecal corticosterone metabolite concentrations. Tph2\(^{−/−}\) males displayed increased impulsivity and high aggressiveness. Tph2\(^{−/−}\) females displayed greater emotional reactivity to aversive conditions as reflected by changes in behaviors at baseline including increased freezing and decreased locomotion in novel environments. However, both Tph2\(^{−/−}\) male and female mice were resilient to CMS-induced hyperlocomotion, while CMS intensified conditioned fear responses in a GxE-dependent manner.
Conclusions
Our results indicate that 5-HT mediates behavioral responses to environmental adversity by facilitating the encoding of stress effects leading to increased vulnerability for negative emotionality.
Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy
(2015)
Diabetic neuropathy (DNP), afflicting sensory and motor nerve fibers, is a major complication in diabetes.The underlying cellular mechanisms of axon degeneration are poorly understood. IGFBP5, an inhibitory binding protein for insulin-like growth factor 1 (IGF1) is highly up-regulated in nerve biopsies of patients with DNP. We investigated the pathogenic relevance of this finding in transgenic mice overexpressing IGFBP5 in motor axons and sensory nerve fibers. These mice develop motor axonopathy and sensory deficits similar to those seen in DNP. Motor axon degeneration was also observed in mice in which the IGF1 receptor(IGF1R) was conditionally depleted in motoneurons, indicating that reduced activity of IGF1 on IGF1R in motoneurons is responsible for the observed effect. These data provide evidence that elevated expression of IGFBP5 in diabetic nerves reduces the availability of IGF1 for IGF1R on motor axons, thus leading to progressive neurodegeneration. Inhibition of IGFBP5 could thus offer novel treatment strategies for DNP.
Fabry disease is an X-linked lysosomal storage disorder due to impaired activity of alpha-galactosidase A with intracellular accumulation of globotriaosylceramide. Associated small fiber pathology leads to characteristic pain in Fabry disease. We systematically assessed sensory system, physical activity, metabolic parameters, and morphology of male and female mice with alpha-galactosidase A deficiency (Fabry ko) from 2 to 27 months of age and compared results with those of age- and gender-matched wild-type littermates of C57Bl/6J background. Results From the age of two months, male and female Fabry mice showed mechanical hypersensitivity (p < 0.001 each) compared to wild-type littermates. Young Fabry ko mice of both genders were hypersensitive to heat stimulation (p < 0.01) and developed heat hyposensitivity with aging (p < 0.05), while cold hyposensitivity was present constantly in young (p < 0.01) and old (p < 0.05) Fabry ko mice compared to wild-type littermates. Stride angle increased only in male Fabry ko mice with aging (p < 0.01) in comparison to wild-type littermates. Except for young female mice, male (p < 0.05) and female (p < 0.01) Fabry ko mice had a higher body weight than wild-type littermates. Old male Fabry ko mice were physically less active than their wild-type littermates (p < 0.05), had lower chow intake (p < 0.001), and lost more weight (p < 0.001) in a one-week treadmill experiment than wild-type littermates. Also, Fabry ko mice showed spontaneous pain protective behavior and developed orofacial dysmorphism resembling patients with Fabry disease.
Conclusions. Mice with alpha-galactosidase A deficiency show age-dependent and distinct deficits of the sensory system. alpha-galactosidase A-deficient mice seem to model human Fabry disease and may be helpful when studying the pathophysiology of Fabry-associated pain.
Background
Fabry-associated pain may be the first symptom of Fabry disease (FD) and presents with a unique phenotype including mostly acral burning triggerable pain attacks, evoked pain, pain crises, and permanent pain. We recently developed and validated the first Fabry Pain Questionnaire (FPQ) for adult patients. Here we report on the validation of the self-administered version of the FPQ that no longer requires a face-to-face interview but can be filled in by the patients themselves allowing more flexible data collection.
Methods
At our Würzburg Fabry Center for Interdisciplinary Treatment, Germany, we have developed the self-administered version of the FPQ by adapting the questionnaire to a self-report version. To do this, consecutive Fabry patients with current or past pain history (n = 56) were first interviewed face-to-face. Two weeks later patients’ self-reported questionnaire results were collected by mail (n = 55). We validated the self-administered version of the FPQ by assessing the inter-rater reliability agreement of scores obtained by supervised administration and self-administration of the FPQ.
Results
The FPQ contains 15 questions on the different pain phenotypes, on pain development during life with and without therapy, and on impairment due to pain. Statistical analysis showed that the majority of questions were answered in high agreement in both sessions with a mean AC1-statistic of 0.857 for 55 nominal-scaled items and a mean ICC of 0.587 for 9 scores.
Conclusions
This self-administered version of the first pain questionnaire for adult Fabry patients is a useful tool to assess Fabry-associated pain without a time-consuming face-to-face interview but via a self-reporting survey allowing more flexible usage.
Interleukin-4 (IL-4) is an anti-inflammatory and analgesic cytokine that induces opioid receptor transcription. We investigated IL-4 knockout (ko) mice to characterize their pain behavior before and after chronic constriction injury (CCI) of the sciatic nerve as a model for neuropathic pain. We investigated opioid responsivity and measured cytokine and opioid receptor gene expression in the peripheral and central nervous system (PNS, CNS) of IL-4 ko mice in comparison with wildtype (wt) mice. Naïve IL-4 ko mice displayed tactile allodynia (wt: 0.45 g; ko: 0.18 g; p<0.001), while responses to heat and cold stimuli and to muscle pressure were not different. No compensatory changes in the gene expression of tumor necrosis factor-alpha (TNF), IL-1β, IL-10, and IL-13 were found in the PNS and CNS of naïve IL-4 ko mice. However, IL-1β gene expression was stronger in the sciatic nerve of IL-4 ko mice (p<0.001) 28 days after CCI and only IL-4 ko mice had elevated IL-10 gene expression (p = 0.014). Remarkably, CCI induced TNF (p<0.01), IL-1β (p<0.05), IL-10 (p<0.05), and IL-13 (p<0.001) gene expression exclusively in the ipsilateral spinal cord of IL-4 ko mice. The compensatory overexpression of the anti-inflammatory and analgesic cytokines IL-10 and IL-13 in the spinal cord of IL-4 ko mice may explain the lack of genotype differences for pain behavior after CCI. Additionally, CCI induced gene expression of μ, κ, and δ opioid receptors in the contralateral cortex and thalamus of IL-4 ko mice, paralleled by fast onset of morphine analgesia, but not in wt mice. We conclude that a lack of IL-4 leads to mechanical sensitivity; the compensatory hyperexpression of analgesic cytokines and opioid receptors after CCI, in turn, protects IL-4 ko mice from enhanced pain behavior after nerve lesion.
Background
"Negative affect" is one of the major migraine triggers. The aim of the study was to assess attentional biases for negative affective stimuli that might be related to migraine triggers in migraine patients with either few or frequent migraine and healthy controls.
Methods
Thirty-three subjects with frequent migraine (FM) or with less frequent episodic migraine, and 20 healthy controls conducted two emotional Stroop tasks in the interictal period. In task 1, general affective words and in task 2, pictures of affective faces (angry, neutral, happy) were used. For each task we calculated two emotional Stroop indices. Groups were compared using one-way ANOVAs.
Results
The expected attentional bias in migraine patients was not found. However, in task 2 the controls showed a significant attentional bias to negative faces, whereas the FM group showed indices near zero. Thus, the FM group responded faster to negative than to positive stimuli. The difference between the groups was statistically significant.
Conclusions
The findings in the FM group may reflect a learned avoidance mechanism away from affective migraine triggers.
NKG2D is an activating receptor on T cells, which has been implicated in the pathogenesis of autoimmune diseases. T cells are critically involved in idiopathic inflammatory myopathies (IIM) and have been proposed as specific therapeutic targets. However, the mechanisms underlying T cell-mediated progressive muscle destruction in IIM remain to be elucidated. We here determined the involvement of the NKG2D - IL-15 signaling pathway. Primary human myoblasts expressed NKG2D ligands, which were further upregulated upon inflammatory stimuli. In parallel, shedding of the soluble NKG2D ligand MICA (sMICA) decreased upon inflammation potentially diminishing inhibition of NKG2D signaling. Membrane-related expression of IL-15 by myoblasts induced differentiation of naive CD8\(^+\) T cells into highly activated, cytotoxic \(CD8^+NKG2D^{high}\) T cells demonstrating NKG2D-dependent lysis of myoblasts in vitro. \(CD8^+NKG2D^{high}\) T cell frequencies were increased in the peripheral blood of polymyositis (PM) patients and correlated with serum creatinine kinase concentrations, while serum sMICA levels were not significantly changed. In muscle biopsy specimens from PM patients expression of the NKG2D ligand MICA/B was upregulated, IL-15 was expressed by muscle cells, CD68\(^+\) macrophages as well as CD4\(^+\) T cells, and \(CD8^+NKG2D^+\) cells were frequently detected within inflammatory infiltrates arguing for a local signaling circuit in the inflammatory muscle milieu. In conclusion, the NKG2D - IL-15 signaling pathway contributes to progressive muscle destruction in IIM potentially opening new therapeutic avenues.
Objective. Current evidence indicates that there is no single ideal treatment for fibromyalgia syndrome (FMS). First choice treatment options remain debatable, especially concerning the importance of complementary and alternative medicine (CAM) treatments. Methods. Three evidence-based interdisciplinary guidelines on FMS in Canada, Germany, and Israel were compared for their first choice and CAM-recommendations. Results. All three guidelines emphasized a patient-tailored approach according to the key symptoms. Aerobic exercise, cognitive behavioral therapy, and multicomponent therapy were first choice treatments. The guidelines differed in the grade of recommendation for drug treatment. Anticonvulsants (gabapentin, pregabalin) and serotonin noradrenaline reuptake inhibitors (duloxetine, milnacipran) were strongly recommended by the Canadian and the Israeli guidelines. These drugs received only a weak recommendation by the German guideline. In consideration of CAM-treatments, acupuncture, hypnosis/guided imagery, and Tai Chi were recommended by the German and Israeli guidelines. The Canadian guidelines did not recommend any CAM therapy. Discussion. Recent evidence-based interdisciplinary guidelines concur on the importance of treatment tailored to the individual patient and further emphasize the need of self-management strategies (exercise, and psychological techniques).
This review addresses the current status of drug therapy for the management of fibromyalgia syndrome (FMS) and is based on interdisciplinary FMS management guidelines, meta-analyses of drug trial data, and observational studies. In the absence of a single gold-standard medication, patients are treated with a variety of drugs from different categories, often with limited evidence. Drug therapy is not mandatory for the management of FMS. Pregabalin, duloxetine, milnacipran, and amitriptyline are the current first-line prescribed agents but have had a mostly modest effect. With only a minority of patients expected to experience substantial benefit, most will discontinue therapy because of either a lack of efficacy or tolerability problems. Many drug treatments have undergone limited study and have had negative results. It is unlikely that these failed pilot trials will undergo future study. However, medications, though imperfect, will continue to be a component of treatment strategy for these patients. Both the potential for medication therapy to relieve symptoms and the potential to cause harm should be carefully considered in their administration.
High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know
(2014)
Neuropathic pain is a frequent and disabling condition with diverse underlying etiologies and is often difficult to treat. Systemic drug treatment is often limited in efficacy. Furthermore, adverse effects may be a limiting factor when trying to reach the necessary dose. Analgesics that can be applied topically have the potential to largely overcome this problem. They may be of particular advantage in localized neuropathic pain syndromes such as postherpetic neuralgia or small fiber neuropathy. Capsaicin, the pungent component of chili peppers, is a natural ligand of the transient receptor potential vanilloid 1 channel and has long been used as topically applicable cream with concentrations of 0.025 to 0.075%. In 2009, a high-concentration transdermal capsaicin 8% patch (Qutenza ; Acorda Therapeutics, Inc., Ardsley, NY, USA; Astellas Pharma Europe Ltd., Chertsey, Surrey, UK) was introduced for the treatment of peripheral neuropathic pain syndromes other than of diabetic origin in adults. It has since been widely used in diverse neuropathic pain disorders. In this review article, we summarize current knowledge on Qutenza, its advantages and problems, and expose unmet needs.